Pharma.AI launches to apply artificial intelligence to drug discovery and development
Insilico Medicine, one of the leaders in advanced signaling pathway
activation analysis and deep learning for aging and cancer research is
proud to announce the formation of the Pharmaceutical Artificial
Intelligence division focused on applying latest advances in artificial
intelligence to streamline drug discovery and drug repurposing processes
and significantly cutting time to market.
With the exception of cancer immunology, most of the pharmaceutical
companies are facing declining returns on their R&D investments and
are not open to external innovation in early stage development.
Pharma.AI aims to bridge this gap by providing cutting-edge machine
learning services delivered by an experienced team of bioinformatics and
deep learning experts working with millions of drugs, annotated gene
expression samples and blood biochemistry data sets that can be used to
augment customer's data.
"Since its inception Insilico Medicine is taking the umbrella view
on aging research developing biomarkers and drug candidates in a broad
number of fields. We collaborate with some of the largest pharmaceutical
companies, cosmetics companies and academic institutions on a number of
disease- or drug-specific projects. However, our focus on aging and "we
do everything" approach is confusing for many of our customers and
partners and with the launch of Pharma.AI as a division, we will
highlight a core part of our business and explore the possibility of
spinning it off as a separate company in the future", said Alex
Zhavoronkov, PhD, CEO of Insilico Medicine, Inc.

With 11 highly-expert machine learning experts worldwide, Pharma.AI
team is developing deep learned transcriptomics-, proteomics-, blood
biochemistry-based biomarkers of multiple diseases, predictors of
alternative therapeutic uses of multiple drugs and analytical tools for
high-throughput screening. Pharmaceutical companies utilizing Broad
Institute's Connectivity Map or LINCS projects of pipelines will find
powerful analytical drug discovery tools readily available.
"I am happy to join Pharma.AI division as a research scientist
focusing on interpreting the results of our AI analytical systems in
skin care applications. I am already supporting this team as a
geneticist, but with a full-time appointment I have a chance to help
transform the pharmaceutical industry forever. I am also happy with
Insilico Medicine's mission to empower women in emerging geographies and
giving us visibility and skills that will be in high demand over the
next two decades when many other jobs will be lost to automation", said
Polina Mamoshina, senior research scientist at Insilico Medicine.
About Insilico Medicine, Inc
Insilico Medicine, Inc. is a bioinformatics company located at the
Emerging Technology Centers at the Johns Hopkins University Eastern
campus in Baltimore. It utilizes advances in genomics, big data analysis
and deep learning for in silico drug discovery and drug repurposing for
aging and age-related diseases. The company pursues internal drug
discovery programs in cancer, Parkinson's, Alzheimer's, sarcopenia and
geroprotector discovery and provides services to pharmaceutical
companies. Brief company video:
https://www.youtube.com/watch?v=l62jlwgL3v8
Комментариев нет:
Отправить комментарий